Effect of Alirocumab(Proprotein Convertase Subtilisin/Kexin type9 Inhibitor) and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular Ultrasound
- Sponsor
- Kobe University
- Study ID
- NCT03529253
- Phase
- PHASE4
- Status
- Unknown
Conditions
- Angina Pectoris
- Coronary Artery Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 20 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Alirocumab 75 MG/ML [Praluent]+ Rosuvastatin 10mg/daily — DRUGAlirocumab group receive Alirocumab75mg/2week subcutaneous injection plus Rosuvastatin10mg/daily by oral for 9 months.
- Rosuvastatin calcium10mg — DRUGRosuvastatin10mg/daily by oral for 9 months.
Study Details
The purpose of this study is to verify whether additional administration of Alirocumab exerts a stronger stabilizing effect on the vulnerable plaque in CAD, compared with statin alone administration in patients receiving PCI. Therefore, the change in maxLCBI (4 mm) of the coronary artery 9 months after administration by addition administration of Alirocumab is evaluated as the main evaluation item as compared with statin administration alone for patients who have CAD and received PCI. Also, change of plaque properties is compared with baseline and evaluated. This study is a single-center, randomized, open-label study, using alirocumab, rosuvastatin as test drugs. Based on the findings obtained in this study, it is possible to clarify the mechanism of stabilization of the plaque in a patient with coronary artery disease, which in turn suppresses the progress of plaque in coronary artery disease, resulting in primary or secondary There is a possibility that it can contribute to prevention.
Key Dates
- Start date
- Apr 1, 2018
- Status verified
- Aug 2018
- Primary completion
- Sep 30, 2020
- Completion
- Sep 30, 2020
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Intensive therapy groupAlirocumab group is Alirocumab75mg/2week plus Rosuvastatin10mg/daily.
- Active Comparator: Standard therapy groupThe standard therapy group is Rosuvastatin10mg/daily alone.
Primary Outcome Measure
maxLCBI (4mm) [ Time Frame: baseline and 9 months ]
Central Contacts
- Hiromasa Otake, MD, PhD078-382-5846
Related Studies
- Evaluating Cardiovascular Phenotypes Using Induced Pluripotent Stem CellsEnrolling By Invitation · Scripps Translational Science Institute · La Jolla, California
- Product Surveillance RegistryRecruiting · Medtronic · Birmingham, Alabama
- Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)PHASE2 · Not Yet Recruiting · Cell>Point LLC · Oklahoma City, Oklahoma
- Factors Affect Outcomes in Cardiovascular SurgeryRecruiting · University of California, Davis · Sacramento, California